[{"innerBlocks":[],"name":"core\/freeform","postId":392,"blockType":{"name":"core\/freeform","keywords":[],"attributes":{"content":{"type":"string","source":"raw"},"lock":{"type":"object"}},"providesContext":[],"usesContext":[],"selectors":[],"supports":{"className":false,"customClassName":false,"reusable":false},"styles":[],"variations":[],"apiVersion":3,"title":"Classic","description":"Use the classic WordPress editor.","category":"text"},"originalContent":"The Food and Drug Administration has given clearance to the Dexcom G6 Pro single-use continuous glucose monitoring system to enable healthcare providers to tailor treatment plans for diabetic patients.Patients wear a single-use, disposable sensor for 10 days and then Dexcom\u2019s CLARITY software enables providers to put together reports on glucose patterns, trends and statistics that can be retrospectively reviewed with patients when they return to their physician\u2019s office.According to Dexcom, the G6 Pro is the first and only single-use, professional CGM that gathers patients\u2019 real-time glucose data over a 10-day period and operates in both blinded and unblinded modes.\u201cIn blinded mode, real-time glucose data is hidden from the patient and reviewed retrospectively with their healthcare professional at the end of the session,\u201d according to the vendor\u2019s announcement. \u201cIn unblinded mode, patients can see their glucose data throughout the 10-day sensor wear to gain insights and make treatment decisions in real time.\u201dThe Dexcom G6 Pro, which is slated to begin shipping in early 2020, is indicated for management of diabetes in persons two years of age and older. The system is FDA-permitted to make diabetes treatment decisions without confirmatory fingersticks or calibration.

The G6 Pro automatically provides glucose values every five minutes and\u2014in unblinded mode only\u2014alerts users of dangerous high and low glucose levels on their smart device. In addition, the glucose data can be shared with up to 10 followers.\u201cDexcom G6 Pro will enable healthcare providers to set up their patients with CGM in minutes,\u201d said Davida Kruger, a diabetes specialist in the Division of Endocrinology, Diabetes, Bone and Mineral Disorders at the Henry Ford Health System in Detroit. \u201cThis new professional system will serve as a simple way to obtain data from CGM na\u00efve patients who need glucose insight, but don\u2019t need or want to be monitored around the clock. It will give all my patients a chance to try the Dexcom G6 Pro under a healthcare provider\u2019s supervision before they commit to a personal system.\u201d","saveContent":"The Food and Drug Administration has given clearance to the Dexcom G6 Pro single-use continuous glucose monitoring system to enable healthcare providers to tailor treatment plans for diabetic patients.Patients wear a single-use, disposable sensor for 10 days and then Dexcom\u2019s CLARITY software enables providers to put together reports on glucose patterns, trends and statistics that can be retrospectively reviewed with patients when they return to their physician\u2019s office.According to Dexcom, the G6 Pro is the first and only single-use, professional CGM that gathers patients\u2019 real-time glucose data over a 10-day period and operates in both blinded and unblinded modes.\u201cIn blinded mode, real-time glucose data is hidden from the patient and reviewed retrospectively with their healthcare professional at the end of the session,\u201d according to the vendor\u2019s announcement. \u201cIn unblinded mode, patients can see their glucose data throughout the 10-day sensor wear to gain insights and make treatment decisions in real time.\u201dThe Dexcom G6 Pro, which is slated to begin shipping in early 2020, is indicated for management of diabetes in persons two years of age and older. The system is FDA-permitted to make diabetes treatment decisions without confirmatory fingersticks or calibration.

FDA clears practice-owned diabetes management tool

More for you